405 related articles for article (PubMed ID: 26730290)
1. Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.
Schulte C; Westermann D; Blankenberg S; Zeller T
World J Cardiol; 2015 Dec; 7(12):843-60. PubMed ID: 26730290
[TBL] [Abstract][Full Text] [Related]
2. microRNAs in cardiovascular disease - clinical application.
Schulte C; Karakas M; Zeller T
Clin Chem Lab Med; 2017 May; 55(5):687-704. PubMed ID: 27914211
[TBL] [Abstract][Full Text] [Related]
3. Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs.
Chen YT; Wong LL; Liew OW; Richards AM
Cells; 2019 Dec; 8(12):. PubMed ID: 31888288
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure.
Watson CJ; Gupta SK; O'Connell E; Thum S; Glezeva N; Fendrich J; Gallagher J; Ledwidge M; Grote-Levi L; McDonald K; Thum T
Eur J Heart Fail; 2015 Apr; 17(4):405-15. PubMed ID: 25739750
[TBL] [Abstract][Full Text] [Related]
5. Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction.
Oikonomou E; Vogiatzi G; Tsalamandris S; Mourouzis K; Siasos G; Lazaros G; Skotsimara G; Marinos G; Vavuranakis M; Tousoulis D
Biomark Med; 2018 Jul; 12(7):783-797. PubMed ID: 29865857
[TBL] [Abstract][Full Text] [Related]
6. miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure.
Cruz MS; da Silva AMG; de Souza KSC; Luchessi AD; Silbiger VN
Heart Fail Rev; 2020 Mar; 25(2):321-329. PubMed ID: 31254148
[TBL] [Abstract][Full Text] [Related]
7. microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts.
Schulte C; Zeller T
Cardiovasc Diagn Ther; 2015 Feb; 5(1):17-36. PubMed ID: 25774345
[TBL] [Abstract][Full Text] [Related]
8. Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF?
Nair N; Gupta S; Collier IX; Gongora E; Vijayaraghavan K
Int J Cardiol; 2014 Aug; 175(3):395-9. PubMed ID: 25002320
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNA in Heart Failure-Practical Guidebook to Clinical Application.
Gozdowska R; Makowska A; Gąsecka A; Chabior A; Marchel M
Cardiol Rev; 2022 Jan-Feb 01; 30(1):16-23. PubMed ID: 32897886
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress.
Ali Sheikh MS; Salma U; Zhang B; Chen J; Zhuang J; Ping Z
Oxid Med Cell Longev; 2016; 2016():5893064. PubMed ID: 27379177
[TBL] [Abstract][Full Text] [Related]
12. Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition).
Pandey A; Khan H; Newman AB; Lakatta EG; Forman DE; Butler J; Berry JD
Hypertension; 2017 Feb; 69(2):267-274. PubMed ID: 27993954
[TBL] [Abstract][Full Text] [Related]
13. Association of miR-197-5p, a Circulating Biomarker for Heart Failure, with Myocardial Fibrosis and Adverse Cardiovascular Events among Patients with Stage C or D Heart Failure.
Liu W; Zheng J; Dong J; Bai R; Song D; Ma X; Zhao L; Yao Y; Zhang H; Liu T
Cardiology; 2018; 141(4):212-225. PubMed ID: 30836355
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction.
Wong LL; Armugam A; Sepramaniam S; Karolina DS; Lim KY; Lim JY; Chong JP; Ng JY; Chen YT; Chan MM; Chen Z; Yeo PS; Ng TP; Ling LH; Sim D; Leong KT; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Lam CS; Jeyaseelan K; Richards AM
Eur J Heart Fail; 2015 Apr; 17(4):393-404. PubMed ID: 25619197
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients.
Bayés-Genis A; Lanfear DE; de Ronde MWJ; Lupón J; Leenders JJ; Liu Z; Zuithoff NPA; Eijkemans MJC; Zamora E; De Antonio M; Zwinderman AH; Pinto-Sietsma SJ; Pinto YM
Eur J Heart Fail; 2018 Jan; 20(1):67-75. PubMed ID: 28949058
[TBL] [Abstract][Full Text] [Related]
16. Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.
Cypen J; Ahmad T; Testani JM; DeVore AD
Curr Heart Fail Rep; 2017 Oct; 14(5):434-443. PubMed ID: 28803400
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.
Michalska-Kasiczak M; Bielecka-Dabrowa A; von Haehling S; Anker SD; Rysz J; Banach M
Arch Med Sci; 2018 Jun; 14(4):890-909. PubMed ID: 30002709
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs as novel biomarkers for heart failure.
Chen F; Yang J; Li Y; Wang H
Hellenic J Cardiol; 2018; 59(4):209-214. PubMed ID: 29126951
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs in heart failure: from biomarker to target for therapy.
Vegter EL; van der Meer P; de Windt LJ; Pinto YM; Voors AA
Eur J Heart Fail; 2016 May; 18(5):457-68. PubMed ID: 26869172
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders.
Marfella R; Di Filippo C; Potenza N; Sardu C; Rizzo MR; Siniscalchi M; Musacchio E; Barbieri M; Mauro C; Mosca N; Solimene F; Mottola MT; Russo A; Rossi F; Paolisso G; D'Amico M
Eur J Heart Fail; 2013 Nov; 15(11):1277-88. PubMed ID: 23736534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
